United Scientific Group Presents

Virtual Series of Cancer R&D & ICHEM-2020

Immunotherapy in Cancer

Session Speakers

**Joost J. Oppenheim**, NIH/NCI, MD, USA  
**Title**: Identification of Effective Combinations of Immunostimulants to Cure Mouse Tumors

**Guido Kroemer**, Gustave Roussy Comprehensive Cancer Center, INSERM, France  
**Title**: Overcoming a Frequent Inborn Immune Defect in Breast Cancer Therapy

**Lauren V. Wood**, Chief Medical Officer, PDS Biotechnology, NJ  
**Title**: Versamune (R-DOTAP): a Transformative Cationic Lipid Nanoparticle Technology Associated with Type I Interferon Specific Activation and Generation of Antibody, CD8 and CD4 T Cell Responses to Recombinant Proteins and Peptide Tumor Antigens

**Wayne Godfrey**, Vice President of Clinical Development at IGM Bioscience  
**Title**: A Novel Approach to Engineering Antibody Based Immunotherapy

**Scott K. Durum**, NCI/CCR, NIH, MD, USA  
**Title**: Title to be updated

**Eduardo Davila**, University of Colorado CU Comprehensive Cancer Center, CO  
**Title**: Novel Gene Platforms to Maintain the Persistence and Antitumor Activity of TIL-, CAR-, and DC-Based Therapies

**William Hearl**, Ph.D. CEO, Immunomic Therapeutics, MD  
**Title**: To be Updated

**Brian Francica**, Tempest Therapeutics, CA  
**Title**: Dual Antagonism of Prostaglandin Receptors EP2 and EP4 by TPST-1495 Suppresses Tumor Growth and Stimulates Antitumor Immunity

**Jing H. Wang**, University of Colorado Anschutz Medical Campus, CO  
**Title**: MHC Class-I Independent Activation of Virtual-Memory CD8 T Cells Induced by Chemotherapeutic Agent-Treated Cancer Cells

**Pooja Jain**, Drexel University College of Medicine, Philadelphia, PA  
**Title**: The MAPK/ERK-regulated MEF-2 isoforms as potential new target(s) for HTLV-1 induced Adult T-cell leukemia/lymphoma (ATLL)

**Jason D. Marshall**, Leidos Biomedical Research, Inc., NCI Campus at Frederick, MD  
**Title**: Performance Optimization of a Novel HPV VLP Vaccine in Mice with Novel Adjuvants

**Joseph Markowitz**, Moffit Cancer Center, FL  
**Title**: Duality of NO in Melanoma

**Yan Leyfman**, Penn State College of Medicine, PA  
**Title**: Finetune Your CARs: Building the Next Generation of Anti-Cancer Therapies

**Jean Gariepy**, Sunnybrook Research Institute, Toronto, Canada  
**Title**: The COMP Platform: Development of High-Valency Protein-Based Agonists As Immunomodulators